Why ignoring menopause is costing UK companies their best leaders

There’s a specific age at which women are supposed to be entering their most powerful years at work — the point where client relationships, pattern recognition and boardroom instinct finally compound into something a business can’t easily replace. Instead, for a rising number of British companies, that age has quietly become an exit point. Not through redundancy or headhunting, but through the slow attrition of menopause symptoms nobody built a system to catch.

The scale of it is only now becoming visible in the data — and even the data disagrees with itself in a way that’s telling.

What the competing figures actually reveal

Government guidance behind this year’s menopause action plan puts the direct cost of departures at around £1.5 billion a year (FemTech World, 2026; REBA, 2026). A separate analysis, folding in absenteeism and reduced performance among women who stay in role without support, puts the fuller toll closer to £2.88 billion (HR Grapevine, 2026). The gap between those two numbers isn’t a rounding error — it’s the difference between counting who leaves and counting who leaves plus who stays and struggles. That both figures exist, cited by different bodies for different purposes, says something about how recently anyone tried to measure this properly at all.

The age profile matters more than either total. CIPD data shows 17% of working women have considered leaving a job for lack of menopause support, and 6% actually have — but the sharper detail sits underneath: women with problematic symptoms at 50 are 43% more likely to have left their job by 55 (REBA, 2026). That’s precisely the age most women are entering senior leadership, not exiting it. This isn’t a workforce-wide productivity story. It’s a succession story, playing out inside a workforce where women 45–55 are already its fastest-growing group, among more than seven million women aged 40–60 currently in employment.

Why this lands hardest at the top

Replacing anyone at that level is expensive, and the maths gets worse the more senior the role. Oxford Economics puts the cost of replacing a woman on £25,000 who leaves due to menopause at over £30,500 (Women and Equalities Committee, 2022). For senior leaders, industry estimates put replacement cost at up to three times salary — a general rule of thumb for hard-to-replace roles, not a menopause-specific study (HR Grapevine, 2026). Applying that multiple to a director on £90,000 implies a cost approaching £270,000 — our own calculation from that published multiple, meant to illustrate scale rather than stand as an audited figure, and one that still excludes the client relationships and institutional knowledge that don’t transfer with a job description. Legal exposure adds another layer: menopause-related tribunal claims have roughly tripled over the past two years, with payouts now regularly exceeding £60,000 (HR Grapevine, 2026).

None of this shows up as a single line in a set of accounts. It shows up gradually, as a leadership pipeline that looks thinner than it should. Grant Thornton’s Women in Business 2026 report found the proportion of female CEOs in UK mid-market companies has fallen from 24% in 2025 to 17% in 2026 — the lowest in eight years (Business Matters, via Inkl, 2026). It would be wrong to draw a straight line from menopause attrition to that single number. But it’s hard to watch a decade of slow progress unwind in twelve months without asking what’s pulling experienced women out of the pipeline that was supposed to feed it.

The same pattern, without a safety net

Founders face a version of this with none of the corporate scaffolding underneath it — no sick pay, no flexible working policy, no HR function to fall back on. For a founder, menopause symptoms don’t just cost a job; they can cost the growth of the business itself, showing up as paused fundraising, delayed hiring, or ambition quietly scaled back at the exact life stage many founders are running their most established companies.

That has real weight against the wider backdrop. The Alison Rose Review calculated that if women started and scaled businesses at the same rate as men, it would add an estimated £310 billion to the UK economy (Rise Report, 2026). Female founders still receive only around 2% of UK venture capital (150sec, 2026), and just one in five active UK companies is female-led (Funding Circle, 2026).

There’s a second barrier compounding the funding gap, and it’s less obvious: visibility. Angel Academe’s chief executive has argued that the bigger obstacle facing female founders isn’t a shortage of funding schemes so much as being harder for customers and investors to find in the first place (Business Matters, via Inkl, 2026). The same reporting notes that consumer purchase intent nearly doubled once shoppers could identify a product as female-founded, through initiatives such as the “Buy Women Built” mark. Put the two barriers together and a founder managing menopause symptoms is fighting on both fronts at once — less visible, and with less capacity to spend on building visibility — at precisely the point in her business where both would matter most.

Policy is catching up faster than most boardrooms

Government guidance on menopause action plans launched in March 2026, running alongside gender pay gap reporting (FemTech World, 2026). It’s voluntary for now; from April 2027 it becomes mandatory for organisations with 250 or more staff, with plans publicly visible and reviewed by the Fair Work Agency (REBA, 2026), and the Employment Rights Act 2025 has already strengthened the legal ground underneath it (HR Grapevine, 2026). Treating 2027 as the start date, rather than the deadline, is a bet that tribunal risk and reputational exposure won’t move faster than the compliance calendar — a bet the tribunal figures above suggest is already losing.

Act now – don’t wait

What makes this worth acting on now, rather than waiting for the mandate, is how quickly it responds to intervention. Organisations offering specialist menopause support have seen severe symptoms drop by 58% within 180 days, and work-related impairment fall by 15% within just 90 days (HR Grapevine, 2026). Few retention or productivity interventions move that fast. That reframes the whole question: this isn’t a slow cultural shift that takes a decade to show results — it’s closer to fixing a leak that’s been treated as background noise for years.

The growth argument

Britain has spent the last few years debating where economic growth is supposed to come from. Some of the most experienced leadership talent it already has is walking out quietly, mid-career, for reasons that are well understood and largely fixable. World Menopause Day, on 18 October, is a useful marker to work toward — but the case for acting doesn’t need the calendar to make it urgent. The businesses that treat this as a leadership and growth question now will simply have a deeper bench than the ones still treating it as a wellbeing footnote when the 2027 deadline arrives.